English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/143112
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer

AuthorsMiguel-Luken, María José de; Chaves-Conde, Manuel; Miguel-Luken, Verónica de; Muñoz-Galván, Sandra ; López-Guerra, José Luis; Mateos, Juan C.; Pachón, Jerónimo ; Chinchón, David; Suárez, Vladimir; Carnero, Amancio
Issue Date28-Feb-2015
PublisherImpact Journals
CitationOncotarget 6(14): 12625-12636 (2015)
AbstractLarynx cancer organ preservation treatments with chemo and radiotherapy have substantially improved laryngoesophageal dysfunction-free survival. However, both of them lead to a high incidence of acute and chronic toxicities and a significant number of patients relapse. To date, there is no evidence available to establish the group of patients that may benefit from preservation approaches and clinical criteria such as primary tumor extension or pretreatment tracheotomy are not validated. MAP17 is a small non-glycosylated membrane protein overexpressed in carcinomas. The tumoral behavior induced by MAP17 is associated with reactive oxygen species production in which SGLT1 seems involved. In this study we found that the levels of MAP17 were related to clinical findings and survival in a cohort of 58 patients with larynx cancer. MAP17 expression is associated with overall survival (p < 0.001) and laryngoesophageal dysfunction-free survival (p=0.002). Locoregional control in patients with high MAP17 showed better outcomes than those with low MAP17 (p=0.016). Besides, a positive correlation was observed between MAP17 expression and SGLT (p=0.022) and the combination of high levels of MAP17/SGLT also led to an increased overall survival (p=0,028). These findings suggest that MAP17, alone or in combination with SGLT1, may become a novel predictive biomarker for laryngeal carcinoma.
Publisher version (URL)http://doi.org/10.18632/oncotarget.3470
Identifiersissn: 1949-2553
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
MAP17_PDZKIP1_Miguel.pdf1,97 MBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.